Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Hims & Hers Data Shows Personalized GLP-1 Plans Drive Real Weight Loss, Few Side Effects, and Strong Adherence to Care
09:00am, Tuesday, 29'th Jul 2025
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today released new data showing that its personalized, digital-first
Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study
09:25am, Monday, 28'th Jul 2025
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
09:25am, Monday, 28'th Jul 2025
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus® DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus® DehydraTECH-GLP
Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might
09:16am, Saturday, 26'th Jul 2025
GLP-1 agonist drugs like Zepbound and Mounjaro from drugmaker Eli Lilly (LLY 0.84%) continue to rise in popularity as people are hopeful about the weight loss they can achieve with their help. But a g
Global Partners Declares Second-Quarter 2025 Cash Distribution of $0.7500 on Common Units
08:30am, Friday, 25'th Jul 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has
West Pharma Lifts Outlook On Surging GLP-1 Demand, Stock Soars
10:38am, Thursday, 24'th Jul 2025
West Pharmaceutical Services, Inc. WST shares are surging Thursday after the injectable pharmaceutical packaging and delivery systems company delivered a robust beat on its second-quarter 2025 earning
Global Partners LP to Host Second-Quarter 2025 Financial Results Conference Call on August 7, 2025
08:30am, Thursday, 24'th Jul 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that it will release its second-quarter 2025 financial results before t
Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
09:25am, Wednesday, 23'rd Jul 2025
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects DehydraTECH reduces side effects and could support patient re
Weight loss drugs could be a gamechanger for women with a common hormonal disorder
08:00am, Sunday, 20'th Jul 2025
Several women who have reported improvements in symptoms of polycystic ovary syndrome, a common hormonal disorder, after using GLP-1s such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Patients a
Global Partners Announces Cash Distribution on Series B Preferred Units
08:35am, Monday, 14'th Jul 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors (the “Board”) of its general partner, Global GP LLC, has declare
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
09:30am, Thursday, 10'th Jul 2025
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
10:56am, Friday, 04'th Jul 2025
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts
03:05pm, Thursday, 03'rd Jul 2025
VK2735 shows strong early weight-loss data, positioning Viking as a potential third major player in the booming GLP-1 obesity drug market. Despite a sharp stock decline, Viking is well-funded, with $8
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
09:14pm, Tuesday, 01'st Jul 2025
There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk.
Hims & Hers Can Still Thrive Without GLP-1s
02:27pm, Tuesday, 01'st Jul 2025
Hims & Hers has achieved explosive revenue and subscriber growth, driven by its direct-to-consumer telehealth model and expanding product lines. The recent termination of the Novo Nordisk partnership
